Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Cullinan Therapeutics ownership disclosure by Kynam Capital group. The filing reports that Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang beneficially own 3,114,132 shares of Cullinan Therapeutics common stock, equal to 5.27% of the class as of
The disclosure lists shared voting and dispositive power of 3,114,132 shares and zero sole voting or dispositive power. The report includes the issuer CUSIP 230031106 and the filer address in Princeton, New Jersey.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of 1,780 shares of common stock at a weighted average price of $14.14 per share. After this transaction, she directly holds 174,844 shares of Cullinan Therapeutics common stock.
The sale was effected under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. The reported price reflects a weighted average for multiple trades executed between $13.89 and $14.35 per share.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported selling a total of 5,353 shares of common stock in open-market transactions. She sold 3,601 shares on February 24, 2026 at a weighted average price of $14.47 per share and 1,752 shares on February 23, 2026 at a weighted average price of $13.99 per share. These sales were effected under a Rule 10b5-1 trading plan and were described as covering personal income tax obligations upon vesting of restricted stock units. After the transactions, she directly holds 176,624 Cullinan Therapeutics common shares.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed executed an open-market sale of 13,515 shares of common stock at
Cullinan Therapeutics Chief Medical Officer Jeffrey Alan Jones reported an open-market sale of 4,582 shares of common stock at $14.47 per share. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, Jones directly holds 159,968 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics, Inc. Chief Legal Officer Jacquelyn L. Sumer reported an open-market sale of 3,601 shares of common stock at
Jennifer Michaelson reported multiple 10b5-1 sales of common stock under Form 144, covering transactions from
Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes. Jeffrey Alan Jones reported an open-market sale of 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations upon vesting of restricted stock units, and now holds 164,550 shares directly.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported multiple equity transactions in company stock. On February 20, 2026, she exercised stock options for 8,000 shares of common stock at a stated exercise price of
Cullinan Therapeutics Chief Legal Officer sells shares for taxes. Jacquelyn L. Sumer executed an open-market sale of 3,742 shares of Cullinan Therapeutics common stock at $13.62 per share on February 20, 2026 to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly holds 131,690 shares.